MX2023006176A - Nuevos derivados de indazol acetileno. - Google Patents

Nuevos derivados de indazol acetileno.

Info

Publication number
MX2023006176A
MX2023006176A MX2023006176A MX2023006176A MX2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A
Authority
MX
Mexico
Prior art keywords
acetylene derivatives
new indazole
indazole
new
formula
Prior art date
Application number
MX2023006176A
Other languages
English (en)
Spanish (es)
Inventor
Cosimo Dolente
Sander Ulrike Obst
Annick Goergler
Georg Jaeschke
Antonio Ricci
David Stephen Hewings
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023006176A publication Critical patent/MX2023006176A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023006176A 2020-12-01 2021-11-29 Nuevos derivados de indazol acetileno. MX2023006176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
PCT/EP2021/083279 WO2022117477A1 (en) 2020-12-01 2021-11-29 New indazole acetylene derivatives

Publications (1)

Publication Number Publication Date
MX2023006176A true MX2023006176A (es) 2023-06-08

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006176A MX2023006176A (es) 2020-12-01 2021-11-29 Nuevos derivados de indazol acetileno.

Country Status (15)

Country Link
US (1) US20240002390A1 (https=)
EP (1) EP4255908A1 (https=)
JP (1) JP7840327B2 (https=)
KR (1) KR20230116799A (https=)
CN (1) CN116490182A (https=)
AR (1) AR124170A1 (https=)
AU (1) AU2021393722A1 (https=)
CA (1) CA3197659A1 (https=)
CL (1) CL2023001440A1 (https=)
CO (1) CO2023006912A2 (https=)
CR (1) CR20230218A (https=)
IL (1) IL303064A (https=)
MX (1) MX2023006176A (https=)
PE (1) PE20240099A1 (https=)
WO (1) WO2022117477A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008049B (zh) 2019-06-21 2024-07-05 豪夫迈·罗氏有限公司 用于癌症治疗的egfr抑制剂
JP7840324B2 (ja) 2020-12-01 2026-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
JP2025516543A (ja) * 2022-05-13 2025-05-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのアロステリックおよびオルソステリックegfr阻害剤の組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
SG11202011818YA (en) * 2018-06-29 2020-12-30 Hoffmann La Roche Compounds
CN113993591A (zh) * 2019-06-21 2022-01-28 豪夫迈·罗氏有限公司 新egfr抑制剂

Also Published As

Publication number Publication date
CN116490182A (zh) 2023-07-25
US20240002390A1 (en) 2024-01-04
JP7840327B2 (ja) 2026-04-03
PE20240099A1 (es) 2024-01-18
CR20230218A (es) 2023-07-07
CA3197659A1 (en) 2022-06-09
EP4255908A1 (en) 2023-10-11
JP2023550902A (ja) 2023-12-06
WO2022117477A1 (en) 2022-06-09
TW202237611A (zh) 2022-10-01
AR124170A1 (es) 2023-02-22
CL2023001440A1 (es) 2023-12-01
CO2023006912A2 (es) 2023-06-09
AU2021393722A1 (en) 2023-04-13
KR20230116799A (ko) 2023-08-04
IL303064A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CO2023006912A2 (es) Nuevos derivados de indazol acetileno
AR121226A1 (es) Compuestos y usos de estos
MX2025004220A (es) Compuestos triciclicos y sus usos
AR115949A1 (es) Compuestos heterocíclicos
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR066972A1 (es) Derivados azapeptidicos
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
CL2023003662A1 (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
CL2024001481A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CL2022001353A1 (es) Inhibidores de egfr
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
CO2024005362A2 (es) Compuestos de cd73
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
PY2061937A (es) 2- derivados de azaespiro[3.4]octano como agonistas de m4
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
CL2023002908A1 (es) Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3
MX2024008745A (es) Compuesto derivado de 1,3-benzodioxol y composicion farmaceutica que comprende el mismo.
MX2024001265A (es) Compuestos inhibidores de serotonina 5-ht2b.
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.